PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17169804-8	2006	Age < 65 years, serum creatinine < 176.8 micromol L-1 and serum beta 2 microglobulin (beta2M) < 3.5 mg L-1 were associated with longer OS (p = 0.028, 0.045 and 0.019, respectively).	Osmium	144-146	beta-2-microglobulin	Homo sapiens	70-90	
20162541-14	2010	OS was significantly greater for patients with age <52 years (median 27 months vs. 7.9 months, P = 0.031), and there was a trend toward greater OS for those with beta2 microglobulin <2.5 mg/l (median 27 months vs. 7.7 months, P = 0.08).	Osmium	147-149	beta-2-microglobulin	Homo sapiens	165-184	
17169804-8	2006	Age < 65 years, serum creatinine < 176.8 micromol L-1 and serum beta 2 microglobulin (beta2M) < 3.5 mg L-1 were associated with longer OS (p = 0.028, 0.045 and 0.019, respectively).	Osmium	144-146	beta-2-microglobulin	Homo sapiens	92-98	
31348229-8	2019	The 5-year OS was 20% in the group with B2-MG >= 3.5.	Osmium	11-13	beta-2-microglobulin	Homo sapiens	40-45	
15744524-9	2005	In multivariate analysis, pretreatment serum levels of soluble interleukin-2 receptor (sIL-2R) were a significant prognostic factor for EFS, and those of beta2-microglobulin (beta2M) and sIL-2R for OS.	Osmium	198-200	beta-2-microglobulin	Homo sapiens	154-173	
15895115-8	2005	In Cox analysis, it was seen that significantly longer OS occurred for patients who had beta-2-microglobulin <3.5 mg/l (P<0.0001), age <60 years (P=0.001) and albumin > or =35 g/l (P=0.009).	Osmium	55-57	beta-2-microglobulin	Homo sapiens	88-108	
29333404-8	2017	In multivariate analysis, only age, LDH, ECOG performance status, and beta2MG were significantly associated with OS, and we developed a new prognostic model with these 4 factors.	Osmium	113-115	beta-2-microglobulin	Homo sapiens	70-77	
24441948-8	2014	Baseline serum B2M was significantly associated with OS in patients with nasal ENKTL (p < 0.001).	Osmium	53-55	beta-2-microglobulin	Homo sapiens	15-18